Cortexyme Announces Issuance of Composition of Matter Patent for Atuzaginstat by the U.S. Patent and Trademark Office

August 27, 2020

 - New U.S. Patent No. 10,730,826 provides additional composition of matter protection for atuzaginstat (COR388)

- The '826 patent extends the patent term for atuzaginstat to 2037, with a possible patent term extension of up to an additional five years

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Aug. 27, 2020-- Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering potential therapeutics for Alzheimer’s and other degenerative diseases, announced today that the U.S. Patent and Trademark Office ("USPTO") issued U.S. Patent No. 10,730,826 relating to Cortexyme’s lead small molecule, atuzaginstat (COR388).

Cortexyme's ‘826 patent provides additional composition of matter protection for atuzaginstat and gingipain inhibitors, with additional claims pending in related applications. The patent is expected to provide patent protection for atuzaginstat through September 2037, not including a possible patent term extension of up to five years as provided under the Drug Price Competition and Patent Restoration Act (35 U.S.C. §156).

Casey Lynch, Cortexyme’s chief executive officer, co-founder, and chair commented: "We are particularly excited about the issuance of this composition of matter patent for atuzaginstat in anticipation of upcoming results from our GAIN Phase 2/3 clinical trial in the fourth quarter of 2021. The USPTO's issuance of this patent strengthens our intellectual property protection for gingipain inhibitors and atuzaginstat. This patent further supports our ongoing R&D efforts to develop treatments for Alzheimer's and other degenerative diseases and supports the potential expansion of our pipeline into additional indications."

About Cortexyme, Inc.

Cortexyme, Inc. (Nasdaq: CRTX) is a clinical stage biopharmaceutical company pioneering upstream therapeutic approaches designed to improve the lives of patients diagnosed with Alzheimer’s and other degenerative diseases. Based upon the evidence generated to date, Cortexyme is currently advancing its lead therapeutic candidate, atuzaginstat (COR388), in the GAIN Trial, an ongoing Phase 2/3 clinical trial in patients with mild to moderate Alzheimer’s disease. Cortexyme is targeting a specific, infectious pathogen found in the brain of Alzheimer’s patients and tied to neurodegeneration and neuroinflammation in animal models. To learn more about Cortexyme, visit www.cortexyme.com or follow @Cortexyme on Twitter.

Forward-Looking Statements

Statements in this press release contain “forward-looking statements” that are subject to substantial risks and uncertainties. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “expect,” “believe,” “will,” “may,” “should,” “estimate,” “project,” “outlook,” “forecast” or other similar words. Examples of forward-looking statements include, among others, statements we make regarding our business plans and prospects, cash forecasts, the timing and success of our clinical trials and related data, ability to fund planned operating and capital expenditures, the timing of announcements and updates relating to our clinical trials and related data, the timing of and our ability to enroll patients into our clinical trials, and the potential therapeutic benefits, safety and efficacy of our product candidates or library of compounds in the potential treatment of Alzheimer’s Disease and additional indications. Forward-looking statements are based on Cortexyme’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict and could cause actual results to differ materially from what we expect. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, but are not limited to, the risks and uncertainties described in the section titled “Risk Factors” in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 16, 2020, our Quarterly Report on Form 10-Q filed with the SEC on August 14, 2020, and other reports as filed with the SEC. Forward-looking statements contained in this press release are made as of this date, and Cortexyme undertakes no duty to update such information except as required under applicable law.

Investor Contact:
Chris Lowe
Cortexyme, Inc.
Chief Financial Officer
clowe@cortexyme.com

Media Contact:
Hal Mackins
For Cortexyme, Inc.
hal@torchcomllc.com
(415) 994-0040

Source: Cortexyme, Inc.